Stop Calling it “Bad PMS”: Understanding PMDD

by rootin Menstrual Healthon Posted on

Premenstrual Dysphoric Disorder (PMDD) affects an estimated 5-8% of women of reproductive age 1, yet it remains one of the most misunderstood and underdiagnosed conditions in women’s health. PMDD is not just “bad premenstrual syndrome (PMS)”. It is a severe, often disabling form of premenstrual syndrome that can profoundly impact mood, cognition, and physical wellbeing. Symptoms typically emerge one to two weeks before menstruation and subside shortly after it begins, creating a recurring cycle of distress that can dominate a woman’s life.

The effects of PMDD go far beyond mood swings. Many women experience crippling anxiety, depression, irritability, and cognitive fog that disrupt work, relationships, and education. Others struggle with physical symptoms such as fatigue, insomnia, and joint pain. The cumulative burden can be devastating, yet too often invisible; women frequently learn to mask their symptoms or attribute them to stress or character weakness2.

Crucially, this burden is not benign. Research consistently shows that PMDD is associated with a markedly increased risk of suicidal ideation and suicide attempts. Large observational studies report that over one-third of women with PMDD experience suicidal thoughts, and rates of suicide attempts are almost seven times higher than in women without PMDD3. These risks are compounded by delayed diagnosis, dismissal of symptoms, and limited access to appropriate care, underscoring that PMDD is not only a quality-of-life issue but a serious mental health concern with potentially fatal consequences3.

The Social Challenge: Stigma & Misunderstanding

Despite its impact, PMDD remains clouded by stigma and misunderstanding. Women who seek help are often told they are being “too emotional” or that their symptoms are “just hormonal.” Such dismissal is a form of medical gaslighting that prevents timely recognition and appropriate care that could have devastating results. The lack of awareness among both the public and healthcare professionals means that diagnosis can take years, with many women cycling through ineffective treatments for depression or anxiety before PMDD is even considered4.

Stigma also operates at a societal level. Cultural narratives that frame menstruation-related suffering as trivial or exaggerated discourage open discussion and help-seeking, leaving many women to cope in isolation. For those with severe symptoms, this isolation can be particularly dangerous. When distress is repeatedly invalidated, women may internalise the belief that their suffering is a personal failing rather than a treatable medical condition, compounding psychological harm5.

The Scientific Challenge: Understanding the Biology

The biological roots of PMDD are complex but increasingly understood. Unlike PMS, PMDD is not linked to abnormal hormone levels, but rather to an abnormal sensitivity to normal hormonal fluctuations, particularly oestrogen and progesterone. This heightened sensitivity affects brain systems that regulate mood and stress, leading to severe emotional and physical responses during the luteal phase of the menstrual cycle 6,7.

The condition manifests in symptoms such as severe depression, anxiety, irritability, concentration difficulties, and physical pain. Because these overlap with psychiatric disorders, PMDD is frequently misdiagnosed as major depression or bipolar disorder8. The cyclical nature of the symptoms, worsening before menstruation and easing afterward, is a key diagnostic clue that often goes unnoticed.

The Way Forward: Solutions & Hope

Addressing PMDD requires progress on several fronts:     

  • Education and awareness are essential, both for clinicians and for women who may not recognise their symptoms as medical or associated with their menstrual cycle. Better training and patient resources can shorten the path to diagnosis. 
  • Accurate diagnostic criteria and clinical recognition must be embedded in healthcare systems to prevent misdiagnosis and ensure access to appropriate treatments.
  • Evidence-based interventions, including hormonal therapies, selective serotonin reuptake inhibitors (SSRIs), cognitive behavioural therapy, and lifestyle modifications can significantly improve quality of life when tailored to individual needs.
  • Research into the underlying biology must continue, exploring neuroendocrine mechanisms, genetic susceptibility, the impact of stress and lifestyle factors on symptom expression, and potential biomarkers to guide future precision treatments.

Encouragingly, efforts to address these gaps are already underway. The PMDD Project is the UK’s first charity dedicated to supporting people impacted by PMDD by raising awareness, providing support and supporting research. They deliver healthcare professional training, host community support groups across the UK, advocate for policy change, and work to improve institutional understanding of the condition.

Call to Action

To truly improve outcomes for women with PMDD, we must first dismantle the stigma that surrounds it. Talking openly about PMDD, in clinics, workplaces, schools, and homes, helps validate experiences and challenge misconceptions. Clinicians must recognise the seriousness of the condition, and healthcare systems must offer accessible diagnostic and treatment pathways.

Finally, women’s voices should be at the centre of change. Their lived experiences must inform research priorities, clinical guidelines, and public awareness. PMDD is not a character flaw or emotional weakness, it is a recognised medical condition deserving of understanding, empathy, and evidence-based care.

Only through open conversation and scientific commitment can we ensure that no woman is left to endure this silent suffering alone.

References

  1. Mishra, S., & Marwaha, R. (2023, February 19). Premenstrual Dysphoric Disorder. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532307/
  2. Arora, A., Chakraborty, S., & Pandey, R. (2025). Understanding premenstrual dysphoric disorder from a psychosomatic and a sensory perspective. Frontiers in Global Women’s Health, 6. https://doi.org/10.3389/fgwh.2025.1595083
  3. Prasad, D., Wollenhaupt-Aguiar, B., Kidd, K. N., de Azevedo Cardoso, T., & Frey, B. N. (2021). Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: A systematic review and meta-analysis. Journal of Women’s Health, 30(12). https://doi.org/10.1089/jwh.2021.0185
  4. News Desk. (2024, September 18). The PMDD chronicles: How a lack of awareness is impacting women with severe PMS – Mancunian Matters. Mancunian Matters. https://www.mancunianmatters.co.uk/news/18092024-the-pmdd-chronicles-how-a-lack-of-awareness-is-impacting-women-with-severe-pms/
  5. Islas-Preciado, D., Ramos-Lira, L., & Estrada-Camarena, E. (2025). Unveiling the burden of premenstrual dysphoric disorder: a narrative review to call for gender perspective and intersectional approaches. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1458114
  6. Hantsoo, L., & Payne, J. L. (2023). Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA. Neuroscience & Biobehavioral Reviews, 149, 105168. https://doi.org/10.1016/j.neubiorev.2023.105168
  7. Ayhan, İ., Altuntaş, İ., Üzümcü, İ., Erbaş1, O., & 2. (2021). Premenstrual syndrome mechanism in the brain. Demiroglu Science University Florence Nightingale Journal of Medicine, 7(2), 213–224. https://doi.org/10.5606/fng.btd.2021.25069
  8. Beck, L. E., Gevirtz, R., & Mortola, J. F. (1990). The predictive role of psychosocial stress on symptom severity in premenstrual syndrome. Psychosomatic Medicine, 52(5), 536–543. https://doi.org/10.1097/00006842-199009000-00006
Post authorWritten by